Anti-Periostin Antibody Development

Creative Biolabs provides the most complete collection of monoclonal antibodies (mAbs) products the world has ever had. From hybridoma to different display platform, our proprietary antibody platform allows rapid generation and large-scale production of high-affinity antibodies that have great potential in a wide range of human diseases therapeutics. Scientists at Creative Biolabs now provide customized anti-periostin antibody development services for our global clients.

Periostin

Periostin, originally known as osteoblast-specific factor-2 (OSF-2), is a disulfide-linked 90 KDa secretory N-glycoprotein that becomes incorporated into the extracellular matrix (ECM). It is composed of an N-terminal EMI domain rich in cysteine residues (the protein-protein interactions site), four tandem FAS1 domains, each composed of nearly 150 amino acids (aa), and the carboxyl-terminal domain, including a heparin-binding site at its C-terminal end. Periostin is alternatively spliced by proteolysis giving the protein-specific characteristics and functions. The protein binds to a number of ECM proteins by the C-terminus, such as heparin, fibronectin, tenascin C and collagen V, thereby enhancing tumor cell invasiveness by affecting ECM fibrillogenesis. Remarkable, the exon 17 region in periostin is essential to tumor progression and metastasis.

Fig.1 Structure and interactions of periostin. (Alfieri, 2015)

Periostin was associated with cancer as high expression levels were found in patient samples of common solid tumor types such as breast, colon, lung, and pancreatic cancer, as well as melanoma. The expression level correlates with tumor progression and was shown to be especially elevated in the secondary sites in 75% of the lymph node metastases of breast cancer patients. Therefore, periostin qualifies as a tumor marker in the clinic, especially for advanced breast cancer.

Anti-Periostin Antibody

Functions in promoting tumor growth and metastasis suggest that inhibiting the effects of periostin could have a place in anti-tumor therapies. Monoclonal periostin-blocking antibodies such as OC-20, MZ-1, MPC7A9, and MPB4B1 have all exhibited a significant inhibitory effect on metastasis of periostin-positive tumor cells.

Targeting components of the ECM in order to block cancer-driving signaling pathways and to facilitate the penetrance of standard chemo-therapeutics is a promising approach to prevent the life-threatening spread of cancer. Our attention towards this protein is not merely limited to develop inhibitory mAbs, but also extended to related products, such as antibody-drug conjugates (ADCs). Given that angiogenesis is a common feature of all malignancies and tumors express common markers of angiogenesis and markers in ECM are much stable than cellular antigens, a single therapeutic agent should in principle be applicable to a wide range of tumor entities. In fact, papers have drawn a similar conclusion that specifically inhibits FASA-1 domain, via a neutralizing antibody or drug, offers a new class of medication for the treatment of common solid tumor.

Fig.2 Identification of peptides recognized by mAbs within the FASA-1 domain. (Field, 2016)

Creative Biolabs is equipped with state-of-the-art research and manufacturing facilities and dedicated to helping our clients design and prepare highly customized antibody products using our featured services. With novel technique platform and professional experiment services, Creative Biolabs gets ready to provide you with the best anti- periostin antibody development services. Please contact us for more information and a detailed quote.

References

1. Alfieri, C.; et al. Discoidin domain receptor-1 and periostin: new players in chronic kidney disease. Nephrology Dialysis Transplantation. 2015, 30(12), 1965-1971.
2. Field, S.; et al. Novel highly specific anti-periostin antibodies uncover the functional importance of the fascilin 1-1 domain and highlight preferential expression of periostin in aggressive breast cancer. International journal of cancer. 2016, 138(8), 1959-1970.

For Research Use Only. NOT FOR CLINICAL USE.